再鼎医药新十年:在大单品时代迈向盈利

E药经理人
15 Jan

预期2025年底前冲刺盈利,2028年手握15款商业化产品、贡献20亿美元收入,即将挺入中国Biotech“盈利俱乐部”的再鼎医药,做对了什么?1月15日,再鼎医药创始人、董事长兼首席执行官杜莹在第43届摩根大通医疗健康年会(以下简称JPM大会)宣布了公司接下来的两大预期:一,再鼎医药已经站在业绩新拐点,即将在2025年底前实现盈利;二,到2028年,再鼎医药将手握15个商业化产品,攀登20亿美元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10